MW‑9, a chalcones derivative bearing heterocyclic moieties, attenuates experimental autoimmune encephalomyelitis via...

Previous studies have indicated that MW‑9, a chalcones derivative bearing heterocyclic moieties, has considerable anti‑inflammatory activity in vitro. Whether MW‑9 may be used to treat inflammation‑based diseases, such as multiple sclerosis, remains unknown. The present study was designed to determine the effect and underlying mechanism of MW‑9 in experimental autoimmune encephalomyelitis (EAE). Female C57BL/6 mice immunized with MOG_35‑55 were treated with or without MW‑9, then the clinical scores and other relevant parameters were investigated. Production of cytokines and specific antibodies were monitored by ELISA assays. Surface marker, Treg cell, and intracellular cytokines (IL‑17A and IFN‑γ) were detected by flow cytometry, and mRNA expression in the helper‑T (T_H)17 cell‑related signaling pathway was examined by reverse transcription‑quantitative (RT‑q) PCR analysis. T_H17 cell differentiation assay was performed. Herein, the present results demonstrated that oral administration of MW‑9 reduced the severity of disease in EAE mice through slowing down infiltration process, inhibiting the demyelination, blocking anti‑MOG_35‑55 IgG antibody production (IgG, IgG_2a and IgG₃), and decreasing accumulation of CD11b⁺Gr‑1⁺ neutrophils from EAE mice. MW‑9 treatments also led to significantly decreased IL‑17A production and IL‑17 expression in CD4⁺ T‑cells, but had no detectable influence on development of T_H1 and T‑regulatory cells ex vivo. RT‑qPCR analysis showed that within the spinal cords of the mice, MW‑9 blocked transcriptional expression of TH17‑associated genes, including Il17a, Il17f, Il6 and Ccr6. In T_H17 cell differentiation assay, MW‑9 inhibited differentiation of 'naïve' CD4⁺ T‑cells into T_H17 cells and reduced the IL‑17A production. The data demonstrated that MW‑9 could attenuate EAE in part through suppressing the formation and activities of pathogenic T_H17 cells.